Tag:

Moderna Therapeutics

Latest Headlines

Latest Headlines

Much-hyped Moderna barrels into the clinic with 6 human trials planned for '16

Moderna Therapeutics, a superlatively well-funded private biotech, has made the leap from preclinical bluster to first-in-human trials, testing out its inaugural candidate and planning to move 5 more into the clinic this year.

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.

Moderna's billion-dollar R&D shop partners up to finally enter the clinic

Moderna Therapeutics, a high-profile private biotech with scores of preclinical projects, is finally moving toward human trials, recruiting one of the world's largest CROs to help get its much-hyped pipeline moving.

Ex-Moderna chief scientist lands at PureTech to seed new biotechs

Joseph Bolen, who quietly left high-profile biotech Moderna Therapeutics earlier this year, has joined startup factory PureTech Health to help the group ferret out promising technologies and launch new companies.

Moderna joins the personalized cancer vaccine rush with third new venture

Moderna Therapeutics is launching the third new personalized cancer vaccine venture in as many weeks, spinning out its messenger RNA tech into a separate entity dubbed Caperna.

Moderna's top scientist steps down amid a billion-dollar R&D push

Moderna Therapeutics' top scientist has quietly left the much-discussed company after two years at the helm of its R&D operation, walking away from a cash-flush biotech with big ambitions.

Moderna tops CNBC's list of most disruptive new technologies

Promising preclinical work on messenger RNA therapies has provided Moderna Therapeutics with the number one spot on CNBC's list of the most disruptive new technologies now in the spotlight.

Moderna flips mRNA rare-disease programs into its third new venture unit

Shuffling a thick deck of preclinical programs, Moderna Therapeutics has dealt out a fresh biotech hand for the third in its series of venture units tasked with recruiting a new team to shepherd messenger RNA programs into the clinic.

R&D exec Tal Zaks leaps from flagging Sanofi to fast-growing Moderna

While a long list of biopharma companies have been dropping the ax on R&D staffers in recent weeks and months, some of the top execs being shown the exit are finding that new doors are opening as fast as old positions are whisked away. Today, Tal Zaks underscored the bright side of restructuring, being named chief medical officer at Moderna Therapeutics a month after he was among 100 oncology R&D staffers who were ushered out at Sanofi in a recent reorganization.

Big rounds push 2014 biotech venture funding to near-record $6B

With a big assist from Moderna's recent monster round, the biotech industry came within a rounding error of breaking the record for new venture investing in 2014, racking up $5.96 billion in total investments in a frenzied year of deals, data and buyouts, according to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.
'